Seripharm

France Updated 9 July 2026

Seripharm is an API manufacturer based in France. It holds one active US drug master file. Its GMP standing is certified by ANSM (FR). Its most recent recorded inspection, by US FDA, closed on 12 March 2021 as NAI.

active US DMFs

valid CEPs

registered plants 1 with an FDA FEI number

filings across 0 regulators

These figures were checked against the regulators' own files on 25 July 2026

Plants

1 of 1 confirmed

Inspections

5 of 5 confirmed

Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

12 March 2021 NAI US FDA
15 March 2018 VAI US FDA
6 May 2016 NAI US FDA
6 June 2013 VAI US FDA
29 January 2010 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site	FDA FEI
France, France	3002808119
LE MANS, France	Not on file

What they file, and where

Molecule	Regulators	Docs
Paclitaxel	US FDA	1

Also appears on these molecule pages

Paclitaxel API

Filings and GMP by regulator

Regulator	Filings	GMP certificates
ANSM (FR)	None	4

Comparing suppliers?

Choose your molecules and target markets. Seripharm comes back tiered against every other supplier able to file there.

Start for free

No sales call.

Open risk flags

The most recent inspection outcome was NAI, on 12 March 2021.

Sources on this page

FDA: Drug master files, establishment registration, inspection classifications
EDQM: Certificates of suitability
EudraGMDP and national regulators: GMP certificates